FDA.reportPublic FDA data

trastuzumab-qyyp 150 MG Injection [Trazimera]

RxCUI
2472794
RxNorm name
trastuzumab-qyyp 150 MG Injection [Trazimera]
Display name
trastuzumab-qyyp 150 MG Injection [Trazimera]
Full name
trastuzumab-qyyp 150 MG Injection [Trazimera]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:18

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761081Trazimeratrastuzumab-qyyp351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TrazimeraTRASTUZUMAB-QYYPPfizer Laboratories Div Pfizer Incb9c5e894-27d2-4245-a653-df986fed3c562026-04-10Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2472794

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
b9c5e894-27d2-4245-a653-df986fed3c56Trazimera 150 MG Injection [PSN] · trastuzumab-qyyp 150 MG Injection [Trazimera] [SBD] · Trazimera 150 MG Injection [SY]39These highlights do not include all the information needed to use TRAZIMERA safely and effectively. See full prescribing information for TRAZIMERA. TRAZIMERA™ (trastuzumab-qyyp) for injection, for intravenous use Initial U.S. Approval: 2019 TRAZIMERA (trastuzumab-qyyp) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diff20260410